Wird geladen...

Advances in the Understanding of Mechanisms and Therapeutic Use of Bortezomib

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been proven to be a promising target for cancer therapy. Bortezomib is the first U.S. Food and Drug Administration (FDA) approved proteasome inhibitor used in the treatment of newly diagnosed multiple myeloma, relapsed/...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mujtaba, Taskeen, Dou, Q. Ping
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4139918/
https://ncbi.nlm.nih.gov/pubmed/22204764
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!